Business
Director/PDMR Dealing
Director/PDMR Dealing.
About this update from Eco Animal Health Group Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 8223F\n Eco Animal Health Group PLC\n 23 March 2022\n \n \n \n ECO Animal Health Group plc\n (''ECO\", the \"Company\" or the \"ECO Group\") (AIM: EAH)\n \n Director/PDMR Dealings\n \n ECO Animal Health Group plc, a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, has been notified that on 23 March 2022, Christopher Wilks, Chief Financial Officer, purchased 25,000 Ordinary Shares of 5 pence each (\"Ordinary Shares\") at a price of 160 pence per share.\n \n Following this transaction, Christopher Wilks' total interest in the Company is 99,095 Ordinary Shares, representing approximately 0.15 per cent. of the Company's issued share capital.\n \n \n Details of the transactions can be found in the Notification of Dealing Form below.\n \n \n \n For further information please contact:\n \n \n \n \n \n \n \n ECO Animal Health Group plc\n \n \n Marc Loomes (CEO)\n \n \n Christopher Wilks (CFO)\n \n \n \n \n \n \n \n \n \n020 8447 8899\n \n \n \n \n \n \n \n \n \n IFC Advisory \n \n \n Graham Herring \n \n \n Zach Cohen\n \n \n \n \n \n \n \n 020 3934 6630\n \n \n \n \n \n \n \n \n \n Singer Capital Markets (Nominated Adviser & Joint Broker)\n \n \n Mark Taylor\n \n \n George Tzimas\n \n \n \n \n \n \n \n 020 7496 3000\n \n \n \n \n \n \n Investec (Joint Broker)\n \n \n Gary Clarence\n \n \n Alex Penney\n \n \n Carlo Spingardi\n \n \n \n \n \n Peel Hunt LLP (Joint Broker)\n \n \n Dr Christopher Golden\n \n \n James Steel\n \n \n \n \n 020 7597 5970\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n 020 7418 8900\n \n \n \n \n \n \n \n \n \n \n \n Equity Developments\n \n \n Hannah Crowe\n \n \n Matt Evans\n \n \n \n \n 020 7065 2692\n \n \n \n \n \n \n \n \n \n \n \n About ECO Animal Health \n \n \n ECO Animal Health Group plc researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development (\"R&D\") for new products, particularly vaccines, and seeking to in-license new products.\n \n \n \n \n \n \n \n \n \n 1 \n \n \n \n \n \n Detail...